跳至主要内容
临床试验/NCT04865744
NCT04865744已完成4 期

The Effect of Semaglutide on Pituitary Function

University of Tartu1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2021年5月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
10
试验地点
1
主要终点
Growth hormone peak

研究概览

简要总结

The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.

详细描述

The randomized blinded placebo-controlled clinical trial is conducted on 10 healthy volunteers.

5 study subjects receive once 7 mg of oral semaglutide and once placebo. 5 study subjects receive once 14 mg of oral semaglutide and once placebo. The study group and order of administration of study medication are decided on randomization. The placebo and oral semaglutide are administered at least 4 weeks apart.

Blood samples are taken before and during 4 hours after the study medication administration (at 60, 90, 120, 150, 180, and 240 minutes after study medication administration).

The primary endpoint is the peak value of growth hormone measured during the 4 hours after study medication administration.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Age 18-50 years
  • •The body weight >65 kg

排除标准

  • •presence of chronic illness
  • •the daily use of medications
  • •pregnancy
  • •lactation.

研究组 & 干预措施

Placebo

Placebo Comparator

The placebo tablet taken orally with 120 ml of water.

干预措施: Placebo (Drug)

Oral semaglutide 7 mg

Active Comparator

The semaglutide 7 mg tablet taken orally with upto120 ml of water.

干预措施: Semaglutide 7 MG Oral Tablet (Drug)

Oral semaglutide 14 mg

Active Comparator

The semaglutide 14 mg tablet taken with upto 120 ml of water.

干预措施: Semaglutide 14 MG Oral Tablet (Drug)

结局指标

主要结局

Growth hormone peak

时间窗: 60, 90, 120, 150, 180 and 240 minutes after study medication administration

Maximum concentration measured after study medication administration.

次要结局

  • Adrenocorticotropin (ACTH) peak(60, 90, 120, 150, 180 and 240 minutes after study medication administration)
  • Glucose nadir(60, 90, 120, 150, 180 and 240 minutes after study medication administration)
  • Cortisol peak(60, 90, 120, 150, 180 and 240 minutes after study medication administration)
  • Copeptin peak(60, 90, 120, 150, 180 and 240 minutes after study medication administration)
  • Aldosterone peak(60, 90, 120, 150, 180 and 240 minutes after study medication administration)
  • C-peptide peak(60, 90, 120, 150, 180 and 240 minutes after study medication administration)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Vallo Volke

Professor

University of Tartu

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Research study to look at how well semaglutide works in people living with heart failure, obesity and type 2 diabetesHeart failure with preserved ejection fractionDiabetes Mellitus, type 2MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849
EUCTR2020-004170-22-CZovo Nordisk A/S610
进行中(未招募)
1 期
Research study to look at how well semaglutide works in people living with heart failure, obesity and type 2 diabetesHeart failure with preserved ejection fractionDiabetes Mellitus, type 2MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849
EUCTR2020-004170-22-ATovo Nordisk A/S610
进行中(未招募)
1 期
Research study to look at how well semaglutide works in people living with heart failure, obesity and type 2 diabetesHeart failure with preserved ejection fractionDiabetes Mellitus, type 2MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849
EUCTR2020-004170-22-DEovo Nordisk A/S610
进行中(未招募)
1 期
Research study to look at how well semaglutide works in people living with heart failure, obesity and type 2 diabetesHeart failure with preserved ejection fractionDiabetes Mellitus, type 2MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849
EUCTR2020-004170-22-SEovo Nordisk A/S610
进行中(未招募)
1 期
Research study to look at how well semaglutide works in people living with heart failure, obesity and type 2 diabetesHeart failure with preserved ejection fraction and diabetes mellitus type 2MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849
EUCTR2020-004170-22-ITOVO NORDISK. S.P.A.610